CROI 2017 Program and Information

Program and Agenda

Symposium S-2 MULTIDRUG-RESISTANT TB (MDR-TB): THE GOOD, THE BAD, AND THE UGLY Room 606-609 4:00 PM - 6:00 PM Target Audience: This session is directed to clinicians and researchers interested in the pathogenesis, clinical manifestations, diagnosis, treatment and prevention of tuberculosis (TB) and its complications, including HIV and TB co-infection. Level of knowledge: It is assumed that participants are familiar with basic TB biology, epidemiology, clinical features and treatment. Objectives: At the completion of the session, participants will be able to: • Describe the epidemiology of and factors associated with transmission of multidrug resistant TB (MDR-TB) • Identify appropriate regimens utilizing new and investigational drugs for treatment of MDR-TB, including the challenges associated with their use in children • Assess the role of new and existing technologies for diagnosis of MDR-TB Conveners Constance Benson , Univ of California San Diego, San Diego, CA, USA Roxana Rustomjee , NIAID, NIH, DHHS, Rockville, MD, USA 50 MDR-TB EPIDEMIOLOGY AND TRANSMISSION 4:00 DYNAMICS N. Sarita Shah , CDC, Atlanta, GA, USA

51 EMERGING TREATMENT ISSUES INMDR-TB Francesca Conradie , Univ of the WItswatersrand, Johannesburg, South Africa 52 NEWDIAGNOSTIC TECHNOLOGIES FORMDR-TB Catharina C. Boehme , Fndn for Innovative New Diagnostics (FIND), Geneva, Switzerland 4:30 5:00

Oral Sessions • Tuesday

53 THE CHALLENGES OF TREATINGMDR-TB IN CHILDREN 5:30

H. Simon Schaaf , Stellenbosch Univ, Cape Town, South Africa

CROI 2017 43